Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]
- PMID: 39426859
- DOI: 10.1016/j.eururo.2024.10.002
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]
Erratum for
-
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.Eur Urol. 2024 Aug;86(2):90-94. doi: 10.1016/j.eururo.2024.04.025. Epub 2024 May 22. Eur Urol. 2024. PMID: 38782695 Free PMC article. Clinical Trial.